Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Compound contains two or more C(=O)O groups

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514506000 - Ester DOAI

514529000 - Z-C(=O)-O-Y wherein Z is hydrogen or an organic radical bonded to the C(=O) by a carbon and Y is an organic radical bonded to the oxygen by a carbon

514546000 - ZC(=O)OY, wherein Z is an acyclic radical bonded to the C=O by a carbon and Y is an organic radical bonded to the oxygen by a carbon

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514548000 Ring is alcohol moiety 33
Entries
DocumentTitleDate
20100063147Anaplerotic Therapy of Huntington Disease and Other Polyglutamine Diseases - The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.03-11-2010
20090062387METHOD OF PREVENTING NEPHROCALCINOSIS - The present invention provides the invention provides methods of reducing phosphate nephropathy in a mammal suffering from impairment of renal function, including administering to the mammal an amount of citrate that is effective to reduce serum phosphorous concentration.03-05-2009
20110190393NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID - The present invention relates to a novel process for the preparation of γ-amino acids, such as (±)-3-(aminomethyl)-5-methyl-hexanoic acid (1), which is a key intermediate in the preparation of the potent anticonvulsant pregabalin, (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid (2), and its analogues.08-04-2011
20090326069Azelaic acid ester compositions and methods for diagnosing and treating tissue conditions using azelaic acid ester compositions and proteinaceous biomarkers - Therapeutic and cosmetic treatments are performed through the application of azelaic acid ester compositions to patients suffering from or exhibiting tissue inflammation. The diagnosis, characterization and treatment of a patient suffering from or exhibiting tissue inflammation may be enhanced by using selected proteinaceous biomarkers obtained from analysis of said markers by means of multiplexed immunoassay and comparison to the biomarker levels of healthy tissue.12-31-2009
20130079406THERAPEUTIC COMPOSITIONS - Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.03-28-2013
20100041751Method to Reduce Oxidative Damage and Improve Mitochondrial Efficiency - Methods for the reduction of mitochondrial oxidative damage and improved mitochondrial efficiency in an animal by administration of medium chain triglycerides or prodrug of medium chain triglycerides to the animal are provided.02-18-2010
20090306205METHOXYPOLYETHYLENE GLYCOL THIOESTER CHELATE AND USES THEREOF - The present invention is directed generally to protecting cells, tissues and organs against the damaging effects of ionizing or other damaging agents associated with radiation or chemotherapy, or degenerative diseases or processes of various organs that elicit the production of free radicals or oxidants such as peroxides, superoxide anions, hydroxyl radicals or nitric oxides, or heavy metal cations. More particularly, the present invention is concerned with methoxypolyethylene glycol thioester chelate methyl esters that are useful as protectors against tissue damage by penetrating the cell membrane to donate electrons to free radical oxidants and remove heavy metals that may react with peroxides to produce the reactive hydroxyl radical, or remove Ca++ that may be released from organelles. These chelate esters will also have utility in reducing intraocular pressure in glaucoma patients.12-10-2009
20130059910CONJUGATES COMPRISING A GABA- OR GLYCINE COMPOUND, PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS THEREOF AS WELL AS THEIR USE IN TREATING CNS DISORDERS - A novel use of conjugates of psychotropic drugs (e.g., antidepressants or anti-epileptic drugs) and organic acids such as GABA in the treatment of pain is disclosed. A novel GABA conjugate and uses thereof is also disclosed.03-07-2013
20110015268PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising a docusate; an osmotic laxative; and a benzoate.01-20-2011
20110021630METHOD FOR TREATING WOUNDS BY ADMINISTERING FULLERENES - Disclosed herein are methods for treating wounds. In one embodiment, the method comprises: administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene of the formula Z01-27-2011
20080293811External preparation for the the skin - A skin treatment composition that characteristically contains alkylene polyglycol dineopentanoate having a specific structure.11-27-2008
20100305204COMPOSITION USEFUL FOR THE PREVENTION OF ADVERSE EFFECT DUE TO THE USE OF PPAR-GAMMA AGONISTS - The present invention relates to the use of acetyl L-carnitine, or a pharmaceutically acceptable salt thereof, for the prevention of the adverse effects, such as osteoporosis, weight gain and edema, due to the use of PPAR-gamma agonists selected from the group consisting of spirolaxine or a glitazonederivative selected from the group consisting of roglitazone, pioglitazone androsiglitazone.12-02-2010
20100280111SKIN EXTERNAL PREPARATIONS AND COSMETICS - An object of the present invention is to provide skin external preparations and cosmetics which contain a branched acyl carnitine and have excellent formulation stability. A skin external preparation of the present invention includes a carnitine derivative represented by the following Formula (1) and/or a carnitine derivative salt represented by the following Formula (2), and an amphoteric surfactant.11-04-2010
20120289596Dermatological Compositions Comprising a Fat or Oil of an Essential Fatty Acid Triglyceride - The present invention relates to a human beta-defensin inducing agent that comprises at least one fat or oil of an essential fatty acid triglyceride or a derivative thereof as the main active ingredient. It also relates to cosmetic, dermatological and pharmacological formulations comprising the at least one fat or oil.11-15-2012
20110124728DHA ENRICHMENT PROCESS - The present invention relates to a continuous process of DHA enrichment of a solution of fatty acids or derivatives thereof comprising less than 50% of DHA relative to the total fatty acids of the solution or to derivatives thereof, wherein the process comprises the steps of (a) simultaneous countercurrent injection, into a fractionation column, of the flow of the solution of fatty acids or of derivatives thereof and of a flow of supercritical CO05-26-2011
20110301238SEIZURE RELATED DISORDERS AND THERAPEUTIC METHODS THEREOF - Methods of treating seizure disorders by administration of a therapeutically effective amount of at least one precursor of propionyl-CoA in the absence of a ketogenic diet are provided. The present invention particularly applies to administration of triglyceride oils and preferably, triheptanoin and derivatives thereof.12-08-2011
20110301237METHODS AND COMPOSITIONS FOR NOVEL LIQUID CRYSTAL DELIVERY SYSTEMS - Methods of making a liquid crystal mixture essentially comprised of at least one fatty acid ester or fatty acid, at least one polyhydric solvent, and at least one alkali reactant. The resultant mixture includes at least one fatty acid ester or fatty acid, at least one polyhydric solvent, and at least one salt of said fatty acid ester or fatty acid. The resultant mixture exhibits enhanced stability and aqueous solubility of fatty acids and fatty acid esters. When medium chain fatty acid monoglycerides are used in the method, the resultant mixture exhibits antimicrobial efficacy.12-08-2011
20090099258Physiological coolants based on lactoyl esters of menthyl lactate - A method of imparting a physiological cooling effect to a consumer product is disclosed. The method comprises formulating into the consumer product a composition comprising at least one lactoyl ester of menthyl lactate. Also disclosed is a method of providing physiological cooling by contacting skin or mucous membranes with the lactoyl ester compositions. Coolants comprising the lactoyl esters and additional coolants are also disclosed. The lactoyl esters are conveniently prepared from menthol and lactic acid.04-16-2009
20100113594PESTICIDAL COMPOSITION AND METHOD FOR CONTROLLING HARMFUL INSECTS - A pesticidal composition containing: 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate, a saturated hydrocarbon having an initial boiling point of 150 C or higher and a 95%-distillation temperature of 300 C or lower, and at least one alkyl carboxylate ester selected from the group consisting of the following esters (i) to (iii): (i) alkyl alkylcarboxylate esters having 12 to 20 carbon atoms, (ii) dialkyl dicarboxylate esters having 12 to 20 carbon atoms, and (iii) trialkyl acetylcitrate esters having 12 to 20 carbon atoms; has an excellent pesticidal activity.05-06-2010
20100113595Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels.05-06-2010
20100113593TOPICAL FUNGICIDAL AGENTS FOR TREATING NAIL DISORDERS - The invention relates to water-free, topically applicable agents for treating, nail problems caused by mycoses, and for nail care, said agents containing at least one C1-C4 alkyl ester of lactic acid, malic acid, tartaric acid or citric acid and physiologically compatible auxiliary substances. The agents according to the invention can also be used in veterinary medicine for treating fungal infections of hooves, claws and talons of pets, working animals and wild animals in captivity.05-06-2010
20100087525STEREOSELECTIVE ENZYMATIC SYNTHESIS OF (S) OR (R)-ISO-BUTYL-GLUTARIC ESTER - The present invention relates to a stereoselective enzymatic synthesis of (S) or (R)-iso-butyl-glutaric ester, an intermediate of S-Pregabalin.04-08-2010
20090111875Skin care compositions - Provided are compositions which are suitable for topical application to mammalian skin for cleansing and anti-microbial properties. In one embodiment, the compositions include a glyceryl monoazelate monolaurate ester. It is postulated that bacteria on or in the skin may cleave the ester linkage of a compound according to the present disclosure that is applied to the skin, which causes liberation of the acid moiety from the ester, which acid moiety then inhibits or kills the bacterium. Compositions according to the present disclosure may comprise skin creams, soaps, shampoos and lotions, and are especially effective in treating acne and acne-like skin ebullitions. The glyceryl portion of the molecules is believed to facilitate penetration of the ester into the skin prior to release of the azelate or laurate residue.04-30-2009
20090298937Method for Inhibiting the Growth of Bacteria - The present invention is directed to a method for inhibiting the growth of pathogenic bacteria in an infant formula comprising supplementing the infant formula with at least one diglyceride antimicrobial agent.12-03-2009
20110207819Fat Emulsion for Artificially Feeding Seriously Ill Intensive Care Patients - The present invention relates to a pharmaceutical preparation for the prophylaxis and treatment of critical illness polyneuropathy (CIP) and critical illness myopathy (CIM). The invention further relates to an isotonic fat emulsion comprising at least one triglyceride that comprises at least one fatty acid group having an odd number of carbon atoms, wherein the fatty acid group comprises a carbon chain having 5 to 15 carbon atoms.08-25-2011
20100280112Composition Enriched in Diglyceride with Conjugated Linoleic Acid - The present invention relates to an oil composition containing a large amount of a. diglyceride of conjugated linoleic acid (CLA), and more particularly to an oil composition with body weight control, anticancer, antioxidation and immune enhancement functions, which is based on a diglyceride of conjugated linoleic acid resulted from an enzymatic reaction between conjugated linoleic acid obtained from edible oil and glycerol. The inventive oil composition comprises 40-95% by weight of diglycerides, 5-60% by weight of triglycerides, 0.110% by weight of monoglycerides, and 0.02-10% by weight of residues, in which the ratio of conjugated linoleic acid (CLA) to fatty acids contained in the total glycerides is 5-98%. The use of the oil composition provides high-added-value foods, pharmaceutical compositions and foodstuff additives with effects of anticancer, immune enhancement, antioxidation, antichlorestol, growth promotion and the like.11-04-2010
20100280113COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS - The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.11-04-2010
20080269327MAGNESIUM COMPOSITIONS AND USES THEREOF FOR COGNITIVE FUNCTION - A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.10-30-2008
20100137436Bipolar trans carotenoid salts and their uses - The invention relates to trans carotenoid salt compounds, methods for making them, methods for solubilizing them and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.06-03-2010
20120196931Treatment for Multiple Sclerosis - Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.08-02-2012
20090163590PROCESS FOR PRODUCING REFINED AVOCADO OIL RICH IN TRIGLYCERIDES, AND OIL OBTAINABLE BY SAID PROCESS - The present invention concerns a process for producing refined avocado oil rich in triglycerides. The invention also pertains to refined avocado oil rich in triglycerides obtainable by said process. Advantageously, the refined avocado oil of the invention contains a sterols-enriched unsaponifiable fraction. Advantageously, the refined avocado oil of the invention is substantially free of acetogenins and furanic lipids. The invention also concerns compositions containing said oil. The invention also pertains to such compositions for use as a medication, as a dermatological agent, as a cosmetic agent, or as a nutriceutical, for human or animal use.06-25-2009
20090182046Cosmetic Compositions Containing Esters Based on 2-Propylheptanol - Esters of 2-propylheptanol with linear or branched, saturated or unsaturated C07-16-2009
20090182047UTILIZATION OF DIALKYLFUMARATES - The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.07-16-2009
20090197951Substituted Fullerene Formulations and Their Use in Ameliorating Oxidative Stress Diseases or Inhibiting Cell Death - This patent discloses a composition comprising a substituted fullerene, wherein the substituted fullerene comprises a fullerene core (Cn), wherein n is an even integer greater than or equal to 60, and at least one substituent group bonded to at least one carbon atom of the fullerene core, and at least one adjuvant, wherein the adjuvant is an absorption enhancer or bioavailability enhancer. It also discloses methods of using such compositions to ameliorate oxidative stress diseases or inhibit cell death.08-06-2009
20090062386Simulants of Toxants for Training and Testing - Compositions are formulated with generally regarded as safe (GRAS) ingredients for use as chemical simulants of toxants such as chemical warfare agents. The compositions can be used for training exercises, testing, and research studies and they can be applied safely to human skin. They include ultraviolet-excited fluorescent ingredients that make possible visible viewing of the simulants. The chemical simulants have good fidelity with the physical properties of toxants, for example, vapor pressure, volatility, persistence, viscosity, response to oxidative, hydrolysis, and perhydrolysis decontaminants, and they can be detected by commonly used portable instruments used to detect toxants.03-05-2009
20100197785OMEGA-3 FATTY ACID FORTIFIED COMPOSITION - The present invention relates to an omega-3 fortified composition, method for its production and use of said composition as a nutritional, food or pharmaceutical composition.08-05-2010
20090197950Substituted Fullerenes and Their Use as Inhibitors of Cell Death - This patent discloses the use of water-soluble substituted fullerenes as inhibitors of cell death. The substituted fullerenes comprise a fullerene core (Cn) and at least one of: (i) from 1 to 6 (>CX08-06-2009
20090247629Dimer poly-quaternary ester compounds - The present invention relates to a novel class of polymeric compounds having specific quaternized amine based upon a dimer acid reacted with an alkanolamine to make an ester quaternary compound. Dimer acid is a C-36 diacid having a cyclic structure and two amine groups that allow for the synthesis of a high molecular weight cationic compound which is extremely substantitive to human skin and are well tolerated by human tissue making them suitable for use preparation of barrier products for personal care applications. These materials are dimethylaminopropyl amine free, which is highly desirable in personal care applications.10-01-2009
20100273876 ANTIBACTERIAL FORMULATION COMPRISING A DIALKYL SULPHOSUCCINATE AND A CARBANILIDE ANTIBACTERIAL AGENT - Antibacterial formulation containing (a) a dialkyl sulphosuccinate (DAS) or derivative thereof and (b) a carbanilide antibacterial agent such as triclocarban (TCC). The formulation may be for use in the treatment of a bacterial condition, in particular acne, body odour or a condition affecting the oral cavity. It may contain, in addition to the DAS and the carbanilide, (i) a poly-oxyalkylene-based solubilising agent; (ii) an organic solvent; (iii) a thickening agent; and (iv) water.10-28-2010
20100261791Compositions and Methods for Improving or Preserving Brain Function - The present invention is related to mammalian nutrition and effects thereof in individuals with age associated cognitive decline such as Age Associated Memory Impairment (AAMI) or a dementing illness such as Alzheimer's disease or related dementia, or Mild Cognitive Impairment, such as improving performance in, or reversal, prevention, reducing and delaying decline in, one or more of cognitive function, memory, behavior, cerebrovascular function, motor function, and/or brain physiology are seen. In particular, the present invention utilizes medium chain triglycerides, in one embodiment, administered as part of a long-term treatment regimen, to preserve or improve learning, attention, motor performance, cerebrovascular function, social behavior, and to increase activity levels, particularly in aging mammals.10-14-2010
20100261790BODY-WEIGHT MAINTENANCE AND BODY COMPOSITION - Use of a mixture comprising a triglyceride oil having a solid fat content at ambient to body temperature and an emulsifier for the preparation of a pharmacologically active composition for increasing body fat mass loss or maintaining blood pressure in an individual. Such use may be carried out subsequent to a period of weight loss. Preferably, the triglyceride oil is fractiorated oil and the emulsifier is galactolipid.10-14-2010
20130123358Metabolic Benefits to Butyrate as a Chronic Diet Supplement - Sodium butyrate was chronically administrated through diet supplementation at 5% w/w in a high fat diet. Supplementation of butyrate prevented development of insulin resistance and obesity in C57BL/6J mice on a high fat diet, and in mice fed on a regular diet of tributyrin. Fasting blood glucose, insulin, and insulin tolerance were all reserved in the butyrate-treated mice. The body fat content was maintained at 10% without a reduction in food intake. Adaptive thermogenesis and fatty acid oxidation were enhanced. An increase in mitochondria function and biogenesis was observed in the skeletal muscle and brown fat, and Type 1 muscle fiber was enriched in the skeletal muscle. In genetically obese mice, supplementation of butyrate led to an increase in insulin sensitivity and reduction in adiposity. Dietary supplementation of butyrate can prevent and treat diet-induced insulin resistance.05-16-2013
20100144875Compositions and Methods for Preserving Brain Function - Compositions and methods for preventing, reducing, or delaying decline in one or more of cognitive function, motor function, cerebrovascular function, or behavior in animals, particularly geriatric animals, are disclosed. The compositions and methods utilize medium chain triglycerides.06-10-2010
20090076147COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE - Pantoic acid ester neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.03-19-2009
20120196932Use of Medium Chain Triglycerides for the Treatment and Prevention of Alzheimer's Disease and Other Diseases Resulting from Reduced Neuronal Metabolism - Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.08-02-2012
20100210723Lipase inhibitor - An object of the present invention is to provide a fat-soluble lipase inhibitor which can contribute to prevention or treatment of obesity due to excessive fat intake or diseases caused by obesity, can be added to fats and oils of all types, and can mildly inhibit hydrolysis by lipase. The present invention is a lipase inhibitor containing, as the active ingredient, at least one substance which is a fat-soluble substance selected from among SLS type triacylglycerols (i.e., symmetric triacylglycerols composed of S which represents a short-chain fatty acid having from 2 to 6 carbon atoms and L which represents a long-chain fatty acid having from 16 to 22 carbon atoms), LUU type and UUL type triacylglycerols (i.e., asymmetric triacylglycerols composed of L which represents a long-chain saturated fatty acid having from 16 to 22 carbon atoms and U which represents an unsaturated fatty acid having from 16 to 22 carbon atoms) and glyceryl ether lipids wherein a long-chain alkyl or alkenyl chain is attached to the 1- or 3-position of the glycerin via an ether bond.08-19-2010
20110130456Hair Growth Regulating Agent - A hair growth regulating agent containing, as an active ingredient, a compound represented by the following formula (I): [wherein R1 represents a substituted or unsubstituted, linear or branched C2 to C25 alkyl group; a group represented by the following formula (II): (wherein R1′ represents a substituted or unsubstituted, linear or branched C2 to C20 alkylene group, or —(CH2)n-{O—(CH2)m}o-O—(CH2)p- in which each of n, m, o, and p is an integer from 1 to 6; X′ represents —CO—NH—, —O—CO—O—, —NH—CO—, —CO—O—, —O—CO—, or —O—; Y′ represents a substituted or unsubstituted C1 to C4 alkylene group; R2′ represents a hydrogen atom or a C1 to C4 alkyl group; R3′ represents a C1 to C4 alkyl group; and when R2′ and R3′ each represent a C1 to C4 alkyl group, the two alkyl groups may be identical to or different from each other); or a group represented by the following formula (III): (wherein R1′, X′, and Y′ have the same meanings as defined above; R4′, R5′, and R6′, which may be identical to or different from one another, each represent a C1 to C4 alkyl group; and A′- represents a counter ion); X represents —CO—NH—, —O—CO—O—, —NH—CO—, —CO—O—, —O—CO—, or —O—; Y represents a substituted or unsubstituted C1 to C4 alkylene group; R2 represents a hydrogen atom or a C1 to C4 alkyl group; R3 represents a C1 to C4 alkyl group; and when R2 and R3 each represent a C1 to C4 alkyl group, the two alkyl groups may be identical to or different from each other] or a salt of the compound; and/or a quaternary ammonium salt represented by the following formula (IV): (wherein R1, X, and Y have the same meanings as defined above; R4, R5, and R6, which may be identical to or different from one another, each represent a C1 to C4 alkyl group; and A- represents a counter ion).06-02-2011
20090286877PESTICIDAL/OVICIDAL COMPOSITION AND PESTICIDAL/OVICIDAL METHOD - A pesticidal/ovicidal composition comprising (a) 50-99.9 parts by mass of a triglyceride containing not less than 50% of oleic acid as a fatty acid component; (b) 0.1-20 parts by mass of a nonionic surface active agent; and (c) 0-30 parts by mass of a glycerin derivative. The composition according to the invention has not only a pesticidal activity but also an ovicidal activity on crop pests, and provides a safe and high pesticidal/ovicidal effect.11-19-2009
20120142773USE OF PUFAS FOR TREATING SKIN INFLAMMATION - The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I),06-07-2012
20130131169COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME - Disclosed is a cooling sensation agent composition or sensory stimulation agent composition which contains at least one of diester compounds of dicarboxylic acid represented by the formula (1) wherein A represents CH05-23-2013
20100311832Lactylates for the prevention and treatment of infections caused by gram positive bacteria in animals - The present invention pertains to the use for preventing or treating intestinal infections caused by gram-positive bacteria in animals of an antibacterial compound selected from lactylate in accordance with formula 1, Formula 1 R2 -COO—[—CH(CH12-09-2010
20090069423COMPOUNDS, COMPOSITIONS AND METHODS FOR PRODUCING ANTIOXIDANTS FROM CARNITINE - Carnitines are nutraceuticals with indications in treating a variety of mental health disorders. A metabolomics-guided bioprocess method is presented to produce longer chain fatty acid esters of carnitines such as polyunsaturated fatty acid esters including eicosapentaenoyl-L-carnitine and/or docosahexaenyl-L-carnitine in germinating plant seeds. The resulting products from the plant seeds are used as a natural nutritional source of powerful human antioxidants.03-12-2009
20100311831Reduction of Sterols and Other Compounds from Oils - A process for the removal of sterols, specifically cholesterol, from a triglyceride oil, preferably a marine triglyceride oil, said process comprising contacting an oil with an absorbent, specifically TRIS YL™, clay or a mixture thereof, heating the mixture to 100° C. to 210° C., preferably 150° C. to 170° C., preferably for a time period of greater than one minute and optionally at a pressure less than 1.33 Pa, preferably less than 1.33 Pa.12-09-2010
20120270943D-aspartic Acid Pro-nutrients with Improved Solubility Characteristics - D-aspartic acid is prepared as its hydrochloride salt or as the hydrochloride salt of its diethyl ester, thereby providing soluble forms of D-aspartic acid that are readily taken up by a human body via its digestive tract. The D-aspartic acid is administered as pills, capsules, powdered drink mixes, beverages, confectionaries, syrups, chewable tablets, nasal sprays, or injectable formulations.10-25-2012
20110245339PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS - Prodrugs made up of biologically-active short-chain fatty acids or derivatives thereof conjugated to neutral or cationic amino acids capable of intracellular transport by ATB10-06-2011
20110124729USE OF HIGHLY-BRANCHED POLYESTERS IN COSMETIC AND DERMATOLOGICAL FORMULATIONS - The present invention relates to compositions which comprise highly branched polyesters, to the use of these highly branched polyesters in cosmetics and dermatology and to substituted highly branched polyesters.05-26-2011
20090215891S-[2-[(1-lminoethy)Amino]Ethyl]-2-Methyl-L-Cysteine Maleate Hydrochloride Crystalline Salt - A novel mixed salt of S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine is disclosed. The novel mixed salt, S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, may be produced to form crystals that may be arranged as generally orderly packed agglomerates, which are particularly useful in making pharmaceutical compositions. Such pharmaceutical compositions are also described, as well as methods to make crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, and methods of treating conditions characterized by an overexpression on nitric oxide from the inducible isoform of nitric oxide synthase using the S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride.08-27-2009
20090023806ALUMINUM-STORAGE DISEASE IMPROVING AGENT - A safe and easy-handling method to eliminate aluminum, which can easily accumulate in a dialysis patient body, in the course of a dialysis treatment and a dialysate used in the above method to eliminate aluminum ions from blood and tissues in the body are provided. A method to eliminate aluminum from a dialysis patient body characterized in that a dialysate mixed with aluminum complexing agents allows formation of complexes with aluminum to excrete aluminum in the form of aluminum complexes into the dialysis drain fluid is also provided. More specifically, the above-mentioned method to eliminate aluminum from the body employs preferably citric acid as an aluminum complexing agent, and the dialysate comprises general dialysate components and 1.7-2.4 mEq/L of citric acid as an aluminum complexing agent.01-22-2009
20110077300Metabolic Benefits to Butyrate as a Chronic Diet Supplement - Sodium butyrate was chronically administrated through diet supplementation at 5% w/w in a high fat diet. Supplementation of butyrate prevented development of insulin resistance and obesity in C57BL/6J mice on a high fat diet, and in mice fed on a regular diet of tributyrin. Fasting blood glucose, insulin, and insulin tolerance were all reserved in the butyrate-treated mice. The body fat content was maintained at 10% without a reduction in food intake. Adaptive thermogenesis and fatty acid oxidation were enhanced. An increase in mitochondria function and biogenesis was observed in the skeletal muscle and brown fat, and Type 1 muscle fiber was enriched in the skeletal muscle. In genetically obese mice, supplementation of butyrate led to an increase in insulin sensitivity and reduction in adiposity. Dietary supplementation of butyrate can prevent and treat diet-induced insulin resistance.03-31-2011
20080249170MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS - A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.10-09-2008
20080249169MAGNESIUM COMPOSITIONS AND USES THEREOF FOR METABOLIC DISORDERS - A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.10-09-2008
20080242723ACYLOXYALKYL CARBAMATE PRODRUGS OF SULFINIC ACIDS, METHODS OF SYNTHESIS, AND USE - Acyloxyalkyl carbamate prodrugs of 3-aminopropylsulfinic acid and analogs thereof, pharmaceutical compositions of 3-aminopropylsulfinic acid and analogs thereof, methods of making prodrugs of 3-aminopropylsulfinic acid and analogs thereof, methods of using prodrugs of 3-aminopropylsulfinic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylsulfinic acid and analogs thereof and sustained release oral dosage forms thereof, which are suitable for oral administration, are also disclosed.10-02-2008
20110257267Reducing the Risk of Pathological Effects of Traumatic Brain Injury - The present disclosure provides methods and compositions for reducing the risk of pathological effects of traumatic brain injury.10-20-2011
20100324136Oily base for a cosmetic and cosmetic comprising the same - The present invention provides an oily base for a cosmetic comprising an ester compound made from a multivalent alcohol and a fatty acid, characterized in that the ester compound is made from pentaerythritol and isononanoic acid and a molar ratio of a pentaerythritol residue and an isononanoic acid residue in the ester compound is 1.0:2.3 to 1.0:4.0. The oily base for a cosmetic of the present invention has proper oily feeling with moistness, no sticky feeling, excellent adhesion to the skin and safety to the skin, and excellent compatibility with oil agents, among others, silicone oil. Furthermore, upon blending the present oily base in a cosmetic, besides having proper emollient property and moisturizing property, the cosmetic exhibits smooth feeling on use, excellent adhesion to the skin and safety to the skin, excellent cosmetic effect-holding ability, and storage stability.12-23-2010
20100190857LIPID-IMPROVING AGENT AND COMPOSITION CONTAINING LIPID-IMPROVING AGENT - A lipid-improving agent containing a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of a triglyceride(s).07-29-2010
20110218242Polyunsaturated Fatty Acids for Treatment of Dementia and Pre-Dementia-Related Conditions - Disclosed are compositions and methods for treating or preventing dementia and pre-dementia-related conditions and/or symptoms or characteristics of such conditions.09-08-2011
20090076146USE OF ACETYL L-CARNITINE FOR THE TREATMENT OF FIBROMYALGIC SYNDROME - The use of acetyl L-carnitine or one of its pharmaceutically acceptable salts is described for the preparation of a medicament and/or dietetic product for the treatment of fibromyalgic syndrome.03-19-2009
20110306664MEDICAL DIETARY COMPOSITION FOR TREATING NEURODEGENERATIVE DISEASES - Medical dietary composition for treating neurodegenerative diseases such as Alzheimer, Parkinson's disease, and more preferably adrenoleukodystrophy comprising a mixture of glyceryl trioleate (GTO), glyceryl trierucate (GTE) and at least one conjugated linoleic acid as active ingredient, in combination with suitable excipients and/or diluents.12-15-2011
20110306663TRIHEPTANOIN DIET FOR ADULT POLYGLUCOSAN BODY DISEASE (APBD) TREATMENT - Compositions and methods for the treatment and management of adult polyglucosan body disease (APBD) are disclosed herein. The APBD patients studied in the present invention experienced stabilization of disease progression and limited functional improvement with dietary triheptanoin (C7TG). The amount of C7TG administered to the patient daily for 6-8 months was 1-2 g/kg/24 hrs. The present invention demonstrates, for the first time, the arrest of clinical deterioration with limited functional recovery in APBD with triheptanoin diet therapy.12-15-2011
20110306666NEW PLANT DERIVED SEED EXTRACT RICH IN ESSENTIALLY FATTY ACIDS DERIVED FROM SALVIA HISPANICA L. SEED: COMPOSITION OF MATTER, MANUFACTURING PROCESS AND USE12-15-2011
20100069490COMPOSITION FOR A PHARMACEUTICAL TREATMENT BASED ON TRIETHYL CITRATE AND ADAPALENE - The invention proposes a composition for pharmaceutical use containing as active principles triethyl citrate and adapalene in quantities efficacious for use in the treatment of cutaneous pathologies of inflammatory origin, caused by bacterial infections or altered lipid metabolism, both in the treatment of chronologic and photo induced cutaneous ageing,03-18-2010
20120004304BILE SALT ADJUVANT FOR ANIMALS FOR IMPROVING FAT UTILIZATION EFFICIENCY IN THE BODIES OF ANIMALS, AND ANIMAL FEED COMPRISING SAME - The present invention relates to a bile salt adjuvant for animals for improving fat utilization efficiency in the bodies of the animals, and to animal feed comprising same. More particularly, the present invention relates to a bile salt adjuvant for animals comprising sodium stearoyl-2-lactylate. The adjuvant is used in animal feed to improve fat utilization efficiency in the bodies of livestock when ingested by said livestock, thereby reducing the amount of fat required to be used in animal feed and improving productivity.01-05-2012
20100204323ANTIMICROBIAL COMPOSITIONS COMPRISING ORGANIC ACID ESTERS AND METHODS FOR REDUCING VIRUS AND BACTERIAL POPULATIONS USING SUCH COMPOSITIONS - Antimicrobial compositions comprising organic acid esters and methods for reducing virus and/or bacteria populations using such compositions are provided. In one embodiment, an antimicrobial composition comprises a virucidally effective amount of an organic acid ester, the organic acid ester having a pK08-12-2010
20110166224DIACYLGLYCEROL RICH FATS, OILS AND FUNCTIONAL FOODS - Disclosed is a fat or oil useful for cooking applications which includes from 10 to 90% by weight diacylglycerols, and has a SFI of at least 15% at room temperature. In particular embodiments, the fat or oil is derived from palm oil, palm kernel oil, coconut oil, sunflower oil, soybean oil, corn oil, rapeseed oil, grape seed oil, rice bran oil, sesame oil, and peanut oil, or any combination thereof. In some cases, the fat or oil exhibits health benefits including lowered serum LDL, raised serum HDL, lowered total serum cholesterol, reduced risk of metabolic syndrome, reduced risk of diabetes mellitus, enhanced fetal health, enhanced insulin sensitivity, reduced risk of hypertension, and enhanced resistance to obesity per unit of consumption. Food compositions and methods of health enhancement utilizing the fats and oils of the invention are also disclosed.07-07-2011
20120022159AMPHIPHILIC STAR-LIKE OR SCORPION-LIKE MACROMOLECULES, VARIOUS COMPOSITIONS AND USES THEREOF - Biomedical uses of amphiphilic macromolecules include the use of such macromolecules in the form of nanoparticle formulations for the sequestration and/or removal of LDL, and for the treatment and prevention of atherosclerosis and atherosclerotic development. The invention also provides the use of amphiphilic macromolecule encapsulates for treating diseases including cancer and inflammation, as well as targeted amphiphilic macromolecules and their use in therapy.01-26-2012
20120208883TREATMENT OF ONCOLOGICAL DISEASES - The present invention relates to the use of acetyl L-carnitine for the preparation of a medicament for the prevention and/or treatment of cancer. Methods of preventing and/or treatment of cancer by administering an effective amount of acetyl L-carnitine to subject in need thereof are also disclosed.08-16-2012
20110184062COMPOSITIONS AND METHODS FOR DRY EYE SYNDROME - Compositions and methods to inhibit dry eye as well as other conditions are provided.07-28-2011
20100093856OMEGA-3 DIGLYCERIDE EMULSIONS - The present invention relates to omega-04-15-2010
20120122978Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment - This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal.05-17-2012
20120165405Anaplerotic Therapy of Huntington Disease and Other Polyglutamine Diseases - The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.06-28-2012
20120165404TREATMENT OF NEURODEGENERATION AND NEUROINFLAMMATION - Methods of treating a subject having a condition characterized by at least one of neurodegeneration and neuroinflammation are provided. Methods of reducing astrogliosis in a subject having a condition characterized by increased astrogliosis are also provided. Methods of providing neuroprotection to a subject in need thereof are also provided.06-28-2012
20120129933CERAMIDE DIMERS AND USE THEREOF AS PHARMACEUTICAL PREPARATION OR COSMETIC PREPARATION - The invention relates to ceramide dimers which are constructed from two ceramide molecules which are crosslinked to each other via their lipophilic end. The ceramide molecules thereby have at least one hydrophilic group at their hydrophilic end for increasing the hydration shell of the dimer. The ceramide dimers according to the invention can be used as pharmaceutical preparation or as cosmetic preparation.05-24-2012
20100222428Fatty Acid Nutritional Supplement - A seven-carbon fatty acid or derivative thereof has been identified as an excellent energy source for humans or human infants. A nutritional supplement suitable for humans or human infants comprising a seven carbon fatty acid chain compound or derivative thereof can be used to increase energy production derived from fatty acid metabolism. For example, administering a seven carbon fatty acid chain compound or derivative thereof can be used to accelerate the growth rate of a prematurely born human infant.09-02-2010
20100273877EMULSIFIED SKIN EXTERNAL PREPARATIONS AND COSMETICS - An emulsified skin external preparation including 0.01 to 10% by mass of a branched acyl carnitine derivative represented by the following Formula (1) and/or a carnitine derivative salt represented by the following Formula (2), and 0.01 to 20% by mass of a nonionic surfactant:10-28-2010
20100292326PHARMACEUTICAL COMPOSITION COMPRISING S-NITROSOGLUTATHIONE AND POLYSACCHARIDE - The invention relates to pharmaceutical compositions comprising S-nitrosoglutathione and one or more polysaccharide-type polimer(s) together with one or more pharmaceutically accepted polymer(s) and additive(s). The invention is based on the discovery that polysaccharide-type polymers (such as chitosan) are capable of stabilizing the otherwise highly labile GSNO.11-18-2010
20120259012Treatment for Amyotrophic Lateral Sclerosis - Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.10-11-2012
20120259011PERSONAL CARE COMPOSITIONS WITH CATIONIC DIESTERS AND DIHYDROXYPROPYL QUATERNARY AMMONIUM SALTS - A personal care composition is provided which includes a diester quat and a polyhydroxy quaternary ammonium salt. Preferably the composition is a lotion or cream which exhibits a dragginess in topical application onto the skin.10-11-2012
20120232142NOVEL USE OF DIMETHYLFUMARATE - Disclosed are a pharmaceutical composition for inhibiting vascular smooth muscle cell proliferation comprising dimethyl fumarate as an effective ingredient, use of dimethyl fumarate for inhibiting vascular smooth muscle cell proliferation, and a method of inhibiting vascular smooth muscle cell proliferation employing the same. Through the present invention, it was found that dimethyl fumarate could inhibit vascular smooth muscle cell proliferation by increasing the activity of AMPK. Accordingly, dimethyl fumarate can be usefully used as an effective ingredient of a medicine for inhibiting vascular smooth muscle cell proliferation.09-13-2012
20120232141COMPOSITIONS COMPRISING A FATTY ACID OIL MIXTURE AND A FREE FATTY ACID, AND METHODS AND USES THEREOF - Compositions comprising a fatty acid oil mixture and at least one free fatty acid, and uses thereof are disclosed. Further disclosed are preconcentrates capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS) or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. Preferred fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a form chosen from ethyl ester and triglyceride.09-13-2012
20110003893AQUEOUS LOXOPROFEN-CONTAINING PATCHES - An aqueous loxoprofen-containing patch is provided, which has good stability and excellent transdermal absorption of loxoprofen. The aqueous patch includes loxoprofen or a salt thereof and triacetin. Specifically, the aqueous patch includes, based on the weight of the adhesive gel base, 0.1 to 5% by weight of loxoprofen or a salt thereof, 0.5 to 5% by weight of triacetin, 1 to 30% by weight of a water-soluble polymer, 0.01 to 5% by weight of a cross-linking agent, 10 to 90% by weight of purified water, and 0 to 20% by weight of an inorganic powder.01-06-2011
20110237667Compositions Containing Diethanol Amine Esterquats - The invention relates to compositions containing one or more compounds of the formula (1), wherein R09-29-2011
20120277316METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE - Methods and compositions for treating or preventing parenteral nutrition associated liver disease are provided. Methods and compositions for advancing enteral tolerance in subjects receiving enteral nutrition are provided. The methods involve the use of omega-3 fatty acid compositions. In some embodiments the omega-3 fatty acid compositions comprise docosahexanoic acid and eicosapentaenoic acid. In some embodiments the omega-3 fatty acid compositions comprise fish oil. In some embodiments the subjects to be treated are receiving parenteral nutrition. In some embodiments the subjects to be treated are infants having a low birth weight, very low birth weight, extremely low birth weight, a low gestational age, short bowel syndrome, necrotizing entercolitis, or any combination thereof.11-01-2012
20110306665COSMETIC PREPARATION, METHOD FOR PRODUCING SAME, COMPOSITION FOR COSMETIC PREPARATIONS, COSMETIC PREPARATION CONTAINING THE COMPOSITION FOR COSMETIC PREPARATIONS AND METHOD FOR PRODUCING SAME, AND CLEANSER FOR INDUSTRIAL USE - The present invention is related to: (1) a cosmetic preparation including an emulsifying agent, 1,3-propanediol (PDO), and a PDO difatty acid ester, wherein the fatty acids constituting the PDO difatty acid ester are one or two or more types of fatty acids selected from isostearic acid, n-octanoic acid, and n-decanoic acid, and a method for producing the cosmetic preparation; (2) a composition for cosmetic preparations, which includes the PDO difatty acid ester, a cosmetic preparation including the composition for cosmetic preparations, and a method for producing the cosmetic preparation; and (3) a cleanser for industrial use, which includes a PDO difatty acid ester that has fatty acid residues of n-octanoic acid and n-decanoic acid. The present invention is able to provide: a cosmetic preparation, a composition for cosmetic preparations, and a cosmetic preparation including the composition for cosmetic preparations, which have excellent cleansing properties, low irritation properties, moisturizing properties, and feeling of use, with reduced load on the environment; methods for producing the same; and, in addition, a cleanser for industrial use which has excellent cleansing properties and low corrosion properties, with reduced load on the environment.12-15-2011
20100130607NEUROPROTECTION IN DEMYELINATING DISEASES - Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.05-27-2010
20110160305Oral Delivery of Therapeutic Doses of Glutathione - Nutritional supplements such as acetyl glutathione with malodor treated to remove the malodor associated with it. Acetyl glutathione, glutathione, esters of glutathione, derivatives of glutathione, and precursors of glutathione and other thiol compounds that may have a strong malodor based on their sulfur content. These compounds are treated with tartaric acid and other products to remove this malodor.06-30-2011
20080249171METHOD FOR ACTIVATING THE LIPID CATABOLIC METABOLISM IN ENTERIC EPITHELIUM AND IMPROVING THE LIPID METABOLISM IN ENTERIC EPITHELIUM - Disclosed are a method for activating lipid metabolism in the small intestine epithelium and also a method for promoting accumulation of fatty acids into the small intestine epithelium, each of which features administering an effective amount of a diacylglycerol. Also disclosed are methods for improving various symptoms in diabetes, which have ingesting a diacylglycerol. Ingestion of the diacylglycerol leads to accumulation of the fatty acids in the small intestine. The fatty acids so accumulated promote induction of β-oxidation, thereby not only activating lipid catabolism but also making it difficult to allow lipids to accumulate as triacylglycerols. This series of actions eventually results in development of lowering action for blood remnant-like lipoprotein level and also lowering action for blood leptin level, and hence, lipid metabolism is improved. Further, energy consumption is enhanced by promoting the induction of β-oxidation and activating lipid catabolism.10-09-2008
20080234372Creatine Salt with Enhanced Nutritional and Therapeutic Efficacy and Compositions Containing Same - The novel salt creatine glycinate and compositions (dietary supplements, energy drinks, and dietetic or pharmaceutical products containing the same are described.09-25-2008
20130178528OMEGA-3 DIGLYCERIDE EMULSIONS - The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides, are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.07-11-2013
20130096193CREATINE BETA-ALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE - Disclosed are creatine β-alaninate, compositions and formulations containing same, and methods of use therefor.04-18-2013
20080200544Oil agent and lubricant agent, moisturizer and external preparation composition containing the same - The present invention provides an oil agent having water solubility and oil solubility, as well as suppressed stickiness when applied to skin to exhibit excellent feeling of use, and also provides a lubricating agent, a moisturizing agent and an external preparation containing said oil agent.08-21-2008
20080200543Immunomodulating Agent, Anti-Cancer Agent and Health Food Containing Monoacetyldiacylglycerol Derivatives - The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against cancer cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect apoptosis. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention can be effectively used for an immunomodulating agent, a sepsis treatment, a cancer treatment, and a health food for an immune modulation or the prevention of cancer.08-21-2008
20100286269Medium-Chain Length Fatty Acids and Glycerides as Nephroprotection Agents - Use of medium-chain length fatty acids such as capric acid, caprylic acid or lauric acid and their salts or mono- or di- or triglycerides as nephroprotection agents to protect against renal failure progression in chronic kidney diseases This includes the treatment of kidney diseases associated with nephrectomy, renal fibrosis, glomerular scelrosis and end-stage renal disease Also includes the protection of the kidney against cytotoxic agent used in chemotherapy or autoimmune diseases or transplantation Further includes the treatment of renal failure progression associated with hypertension, infarct, tumour, diabetes mellitus, autoimmunity or inflammation.11-11-2010
20110237668CHOLINE SALTS OF SUCCINIC ACID FOR THE TREATMENT OF DEPRESSION, ANXIETY, SCHIZOPHRENIA, SLEEP DISORDER, AND EPILEPSY - The present invention relates to compositions and methods for treatment of depression, anxiety, schizophrenia, sleep disorder, or epilepsy comprising monocholine salt of succinic acid of a formula (I) or a pharmaceutically acceptable salt thereof. Preferably, the pharmaceutically acceptable salt is dicholine salt of succinic acid of a formula (II).09-29-2011
20110313039METHOD FOR INCREASING ENDOGENOUS PLASMALOGEN LEVELS IN MAMMALS - The present invention relates generally to compounds such as alkylglycerol and alkoxyglycerol for use in increasing the endogenous level of plasmalogens in a mammal. In particular, these compounds are used for increasing the endogenous plasmalogen level to a level greater than the level in healthy mammals. According to the present invention such compounds are also for use in the prevention or treatment of diseases caused or affected by a decreased endogenous level of plasmalogens. A method for the manufacture of a dietary precursor for the use of the present invention is also part of the present disclosure.12-22-2011
20120259010CATIONIC COSMETIC COMPOSITION - A cosmetic composition is provided which includes a diester quit and a small amount of a potassium salt in an aqueous carrier. Preferably the compositions are lotions and creams which have the benefit of smooth spreadability in topical application onto the skin.10-11-2012
20130184346OIL AND FAT COMPOSITION - Provided is a diacylglycerol-containing fat or oil composition in which a precipitation of crystal is inhibited even under low temperature. The fat or oil composition comprises the following components (A) and (B): (A) a polyglycerin fatty acid ester having an average polymerization degree of glycerin of 20 or more; and (B) 20 mass % or more of diacylglycerol.07-18-2013
20120029076MICRONIZED POLYMER POWDER AND COSMETIC COMPOSITION THEREOF - The invention provides a micronized polymer powder compos Won for the use in personal care and cosmetics, the micronized polymer powder composition comprising at least one thermoplastic polyester based on at least one diol and at least one dicarboxylic acid selected from the group consisting of cyclic and branched aliphatic dicarboxylic acids having 4-12 carbon atoms and aromatic dicarboxylic acids having 8-12 carbon atoms. The present invention provides also a cosmetic composition comprising the at least one micronized polymer powder composition according to the invention.02-02-2012
20130197084NUTRIENT SENSOR - The present invention includes compositions and methods for treating the effects of catabolism in a patient by providing the patient with an amount of an odd-chain fatty acid sufficient to increase the intracellular ratio of AMP to ATP and reduce the activity of AMPK.08-01-2013
20130197083EFFICIENT LIPID DELIVERY TO HUMAN TEAR FILM USING A SALT-SENSITIVE EMULSION SYSTEM - Provided herein are low salt ophthalmic pharmaceutical composition and methods of use thereof, for example, in the treatment of dry eye syndrome.08-01-2013
20120095095USE OF AN OMEGA-3 LIPID-BASED EMULSION FOLLOWING ISCHEMIC INJURY TO PROVIDE PROTECTION AND RECOVERY IN HUMAN ORGANS - The present invention provides methods of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a hypoxic-ischemia insult. The omega-3 lipid-based emulsion preferably comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein fatty acids of the omega-3 trigylceride and/or diglycerides comprise at least 40% EPA and/or DHA. The present invention also provides novel fish-oil compositions for administration after an ischemic insult to limit cell death in the organ that underwent an ischemic event.04-19-2012

Patent applications in class Compound contains two or more C(=O)O groups

Patent applications in all subclasses Compound contains two or more C(=O)O groups